In NSCLC patients, ctDNA sequencing of tumor plasma was reported to be as useful as tumor tissue genotyping to follow the appearance of specific mutations such as EGFR(T790M) mutations at the time of tumor progression (Oxnard et al., 2016). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.